Mayo Clinic

Changes in vaping, other substance use, another side effect of COVID-19

Newswise — EAU CLAIRE, Wis. — Before the COVID-19 pandemic, information about the dangers of vaping was emerging. To investigate the potentially serious health and respiratory implications of vaping, Mayo Clinic researchers wanted to better understand the factors influencing vaping in the community. They were ready to launch a survey of young adults in rural and urban areas when COVID-19 shifted the focus of this survey.

In a recent article in SAGE Open Medicine, the team of investigators report on vaping among adults ages 18–25 during the pandemic and their use of other common substances, such as alcohol, marijuana and tobacco. Inserting a timely additional survey question allowed the team to better understand the effects of compounding daily stresses with a public health crisis.

"As COVID-19 came on the scene, it was primarily thought to have severe respiratory implications," says Pravesh Sharma, M.D., a psychiatrist at Mayo Clinic Health System in Eau Claire, and the study's lead author. "Since we were about to launch a study examining the factors associated with vaping use, which can lead to lung injury, it made sense to revise our questionnaire slightly to address the broader question of the use of vaping and other common substances during a respiratory disease pandemic."

"We found shifts in substance use across the board," says Dr. Sharma. "Most concerning was a significant increase in alcohol use."

About the research

Dr. Sharma and his team developed a survey for patients who were seen for any reason in any outpatient setting at any Mayo Clinic location across the Midwest. The survey was emailed in April to 6,119 adults, ages 18–25 as of Jan. 24, who had been seen in the 4.2 months prior to the survey being sent. The survey came on the heels of state and local governments announcing stay-at-home orders and social distancing guidelines in March due to COVID-19.

The team's planned survey collected information on vaping attitudes and behaviors, as well as the types of vaping products used, including nicotine, marijuana extracts and oils, and other substances. The survey also asked respondents if any of their use had increased or decreased since the COVID-19 pandemic began.

"Substance use is highest in the young adult age group, so we wanted to target this population," says Dr. Sharma. "We would like to understand why they vape and what their attitudes were regarding the potentially harmful nature of vaping."

Of 1,018 respondents, more than half, or 542, reported vaping, or using marijuana, tobacco or alcohol, during the COVID-19 pandemic. Of the respondents, 269 self-reported having an anxiety disorder and 253 reported having depression. Of note, the authors write that study limitations are a reliance on self-reporting of these behaviors and disorders, as well as a 16.6% response rate.

Given that COVID-19 emerged as a primarily respiratory illness and vaping had been increasingly connected to lung damage, the team expected to see a reduction in vaping and smoking. The paper reports that 34.3%, or 186 people, reported a change in their use patterns due to COVID-19:

  • Nearly 70% increased alcohol consumption.
  • Vaping decreased in 44% of people, while 27.9% of people increased use.
  • Tobacco product use decreased in 47.3% of people, while 24.1% of people increased use.
  • Of the 140 people who described a change in marijuana use, 39.2% increased use and 36% decreased use.

Using a previously validated scale, the researchers also measured loneliness among the participants, and collected self-reported depression and anxiety information.

"We did see some reduction in inhaled substances, which could mean that young adults were reacting to the news coverage of COVID-19's respiratory effects," says Dr. Sharma.

"However, we saw that the more lonely, depressed or anxious these young people felt, the more likely they were to change their usage," he says. "They may be trying to cope with social and emotional strain by adding or replacing one substance with another, especially if their access to other support is limited."

"In this time of COVID-19, when we are focused on symptoms of infectious diseases, we need to remain vigilant about changes individuals experience with substance use," says Jon Ebbert, M.D., an internal medicine physician at Mayo Clinic in Rochester, Minn., and a study co-author.

"During the time of this pandemic, screening for substance use, loneliness, anxiety and depression is crucial," states Dr. Sharma. "Just asking, 'How are you holding up during this difficult time' goes a long way."

Drs. Sharma and Ebbert agree it is important for people to be aware of the effect of the pandemic on their well-being.

"As loneliness, anxiety and depression can potentially fuel increases in alcohol consumption during these times of social distancing, introspection with ourselves and observation of our social supports are critical for identifying and addressing substance use issues early," says Dr. Ebbert.

Dr. Sharma suggests checking in regularly with friends and family, inquiring about their well-being, and maintaining a connection. "Social distancing should not mean social isolation," he says.

He and fellow authors also highlight nontraditional socialization opportunities as essential during the continuing COVID-19 pandemic, especially for people with poor emotional health and loneliness.

The senior author of this study is Lindsey Philpot, Ph.D., director of Advanced Analytics and Practice Innovation, Mayo Clinic Department of Medicine. Jordan Rosedahl, a statistical program analyst at Mayo Clinic, also is a co-author.

The research was funded by the Office of Mayo Clinic Health System Research. Conducting research in the diverse communities served by Mayo Clinic in the Midwest allows Mayo to advance knowledge of rural health, a National Institutes of Health designated health disparity. The project also was supported by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery and Mayo Clinic's Survey Research Center.

###

About Mayo Clinic Health System
Mayo Clinic Health System
consists of clinics, hospitals and other facilities that serve the health care needs of people in more than 60 communities in Iowa, Minnesota and Wisconsin. The community-based providers, paired with the resources and expertise of Mayo Clinic, enable patients in the region to receive the highest-quality physical and virtual health care close to home.

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.


Showing results

110 of 4573

close
0.96519